A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 178-187

  Rosenberg, Jonathan E ^a,b,k   Bambury, Richard M ^b   Van Allen, Eliezer M ^a,c   Drabkin, Harry A ^d   Lara, Primo N ^e   Harzstark, Andrea L ^f   Wagle, Nikhil ^c   Figlin, Robert A ^g   Smith, Gregory W ^h   Garraway, Levi A ^c   Choueiri, Toni ^a   Erlandsson, Fredrik ⁱ   Laber, Damian A ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h St Francis Hospital and Health Care Centers   (United States)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j UNIVERSITY OF LOUISVILLE   (United States)

^k NONE   (United States)

more..

Author keywords

Aptamer; AS1411; Nucleolin; Renal cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; APTAMER; AS 1411; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CREATININE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOLIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY METASTASIS; LEUKOCYTE; LYMPHOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MISSENSE MUTATION; MTOR GENE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; CARCINOMA, RENAL CELL; DEMOGRAPHY; EXOME; FEMALE; HUMANS; INDEL MUTATION; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, MOLECULAR; NEOPLASM METASTASIS; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84899122500     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0045-6     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590
3. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
4. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111 (Pubitemid 350296300)
5. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
6. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
7. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151-164
8. Esposito CL, Catuogno S, de Franciscis V, Cerchia L (2011) New insight into clinical development of nucleic acid aptamers. Discov Med 11:487-496
9. Abdelmohsen K, Gorospe M (2012) RNA-binding protein nucleolin in disease. RNA Biol 9:799-808
10. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B (2010) Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One 5:e15787
11. Xu Z, Joshi N, Agarwal A et al (2012) Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. J Neurooncol 108:59-67
12. Chen W, Sridharan V, Soundararajan S et al (2007) Activity and mechanism of action of AS1411 in acute myeloid leukemia cells. Blood 110:1604
13. Xu X, Hamhouyia F, Thomas SD et al (2001) Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276:43221-43230
14. Soundararajan S, ChenW, Spicer EK, Courtenay-Luck N, Fernandes DJ (2008) The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68: 2358-2365 (Pubitemid 351521810)
15. Miller DM, Laber DA, Bates PJ et al (2006) Extended phase I study of AS1411 in renal and non-small cell lung cancers. Ann Oncol 17(suppl 9):ix144-ix157, 450P
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
17. Fisher S, Barry A, Abreu J et al (2011) A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol 12:R1
18. Cibulskis K, Lawrence MS, Carter SL, et al (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31(3):213-219
19. Katoh M (2009) FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol 129:1861-1867
20. Hakimi AA, Pham CG, Hsieh JJ (2013) A clear picture of renal cell carcinoma. Nat Genet 45:849-850
21. Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49
22. Abdelmohsen K, Gorospe M (2012) RNA-binding protein nucleolin in disease. RNA Biol 9:799-808
23. Liu Z, Duan JH, Song YM et al (2012) Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10:148
24. Aravind A, Jeyamohan P, Nair R, et al (2012) AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109(11):2920-2931
25. Kim JK, Choi KJ, Lee M, Jo MH, Kim S (2012) Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamerand microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33:207-217
26. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
27. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib inmelanoma with BRAF V600Emutation. N Engl J Med 364:2507-2516
28. Kerr D (2012) Is oncology ready for 1000 rare diseases? In Medscape oncology. www.medscape.com. Accessed June 2012